SIJ Fusion System

Minimally-Invasive Sacroiliac Joint Fusion System

Executive Summary

Chronic low back pain is the second most common cause of disability in U.S. adults, 15% to 30% which can be attributed to the sacroiliac joint (SIJ). Since FDA approval in 2008, minimally-invasive SIJ fusion surgery has become the standard of care for surgical treatment of SIJ pain. In 2019, in the U.S. alone, tens of thousands of patients benefited from the procedure and – with demand growing at upwards of 15% to 20%+ per year – 200,000+ patients, annually, could benefit. Yet surgeons indicate that current solutions still do not allow for an optimal combination of (1) fast, thorough decortication of the joint space, (2) powerful, controllable compression, and (3) procedural efficiency throughout.

ZIAN’s minimally-invasive, SIJ Fusion System – manufactured in 3D-printed titanium alloy – is designed to address this clinical and market need. In addition to other features, the system is designed to differentially promote bony fusion by allowing for easy, thorough decortication of the joint – requiring far fewer steps than existing, decortication-enabled SIJ fusion technology – and by also allowing for powerful, controllable compression.

SIJ Fusion System

Project Status

Available for exclusive licensing or acquisition

In <12 months, the System’s implants and instruments are moving toward a 5th generation after four internal cadaver labs, one external cadaver lab, and four rounds of 3rd party ASTM testing.

Extensive, iterative system upgrades have been informed by: (1) cadaveric and bench-top testing, (2) extensive feedback from neurosurgeons and orthopedic surgeons, and (3) extensive feedback from industry, via conversations with 20+ potential partners.

Patent pending